Effect of Aztreonam on Throat and Stool Flora of Cancer Patients
Overview
Authors
Affiliations
Eighteen patients with hematological malignancies received aztreonam in one of two dosing regimens, 1 or 2 g every 8 h for a total of 7 to 9 days. Throat and stool cultures were obtained before and during treatment with aztreonam. Aztreonam had little effect on the predominant throat flora. In contrast, facultatively anaerobic gram-negative bacilli were markedly decreased in stools during the administration of aztreonam. Strict anaerobes in the stool were variably affected by aztreonam.
Host impairments in patients with neoplastic diseases.
Donnelly J, Blijlevens N, van der Velden W Cancer Treat Res. 2014; 161:1-41.
PMID: 24706220 PMC: 7119925. DOI: 10.1007/978-3-319-04220-6_1.
Donskey C, Chowdhry T, Hecker M, Hoyen C, Hanrahan J, Hujer A N Engl J Med. 2001; 343(26):1925-32.
PMID: 11136263 PMC: 4370337. DOI: 10.1056/NEJM200012283432604.
Evaluation of aztreonam in the treatment of severe bacterial infections.
Romero-Vivas J, Rodriguez-Creixems M, Bouza E, Hellin T, Guerrero A, Garcia De La Torre M Antimicrob Agents Chemother. 1985; 28(2):222-6.
PMID: 3834832 PMC: 180223. DOI: 10.1128/AAC.28.2.222.
Effect of broad-spectrum parenteral antibiotics on composition of intestinal microflora of humans.
Giuliano M, Barza M, Jacobus N, Gorbach S Antimicrob Agents Chemother. 1987; 31(2):202-6.
PMID: 3566249 PMC: 174692. DOI: 10.1128/AAC.31.2.202.
Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Brogden R, Heel R Drugs. 1986; 31(2):96-130.
PMID: 3512234 DOI: 10.2165/00003495-198631020-00002.